1. Home
  2. NIO vs GH Comparison

NIO vs GH Comparison

Compare NIO & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NIO Inc. American depositary shares each  representing one ordinary share

NIO

NIO Inc. American depositary shares each representing one ordinary share

HOLD

Current Price

$6.36

Market Cap

14.8B

ML Signal

HOLD

Logo Guardant Health Inc.

GH

Guardant Health Inc.

HOLD

Current Price

$82.51

Market Cap

13.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NIO
GH
Founded
2014
2011
Country
China
United States
Employees
45635
N/A
Industry
Auto Manufacturing
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.8B
13.3B
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
NIO
GH
Price
$6.36
$82.51
Analyst Decision
Buy
Strong Buy
Analyst Count
10
19
Target Price
$6.73
$119.79
AVG Volume (30 Days)
30.9M
2.1M
Earning Date
06-02-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
6.74
EPS
N/A
N/A
Revenue
N/A
$982,021,000.00
Revenue This Year
$52.58
$33.30
Revenue Next Year
$18.91
$28.27
P/E Ratio
N/A
N/A
Revenue Growth
N/A
32.88
52 Week Low
$3.35
$36.36
52 Week High
$8.02
$120.74

Technical Indicators

Market Signals
Indicator
NIO
GH
Relative Strength Index (RSI) 53.89 41.54
Support Level $6.28 $82.33
Resistance Level $6.92 $92.73
Average True Range (ATR) 0.27 5.16
MACD -0.07 0.07
Stochastic Oscillator 32.65 41.59

Price Performance

Historical Comparison
NIO
GH

About NIO NIO Inc. American depositary shares each representing one ordinary share

Nio is a leading electric vehicle maker, targeting the premium segment. Founded in November 2014, Nio designs, develops, jointly manufactures, and sells premium smart electric vehicles. The company differentiates itself through continuous technological breakthroughs and innovations such as battery swapping and autonomous driving technologies. Nio launched its first model, its ES8 seven-seater electric SUV, in December 2017, and began deliveries in June 2018. Its current model portfolio includes midsize to large sedans and SUVs. It sold around 326,000 EVs in 2025, accounting for about 2% of the China passenger new energy vehicle market.

About GH Guardant Health Inc.

Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Share on Social Networks: